Neil Minton

1.1k total citations
24 papers, 818 citations indexed

About

Neil Minton is a scholar working on Pathology and Forensic Medicine, Oncology and Rheumatology. According to data from OpenAlex, Neil Minton has authored 24 papers receiving a total of 818 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Pathology and Forensic Medicine, 9 papers in Oncology and 5 papers in Rheumatology. Recurrent topics in Neil Minton's work include Multiple Sclerosis Research Studies (11 papers), Polyomavirus and related diseases (5 papers) and Multiple Myeloma Research and Treatments (4 papers). Neil Minton is often cited by papers focused on Multiple Sclerosis Research Studies (11 papers), Polyomavirus and related diseases (5 papers) and Multiple Myeloma Research and Treatments (4 papers). Neil Minton collaborates with scholars based in United States, Italy and Switzerland. Neil Minton's co-authors include Xavier Montalbán, Ludwig Kappos, James K. Sheffield, Lawrence Steinman, Eva Havrdová, Jeffrey A. Cohen, Krzysztof Selmaj, Bruce Cree, Douglas L. Arnold and Gıancarlo Comı and has published in prestigious journals such as Circulation, Journal of Clinical Oncology and Blood.

In The Last Decade

Neil Minton

23 papers receiving 801 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Neil Minton United States 11 462 208 161 155 146 24 818
P. Gjörstrup Sweden 10 259 0.6× 179 0.9× 107 0.7× 293 1.9× 123 0.8× 15 912
D. Kingsbury United States 13 145 0.3× 243 1.2× 226 1.4× 235 1.5× 86 0.6× 25 768
J. Woody Germany 6 228 0.5× 96 0.5× 274 1.7× 320 2.1× 109 0.7× 7 763
M. Mandel Israel 16 190 0.4× 172 0.8× 93 0.6× 208 1.3× 99 0.7× 30 680
S. Bubel Germany 8 173 0.4× 132 0.6× 55 0.3× 166 1.1× 67 0.5× 9 698
Alexandra Garcia France 12 178 0.4× 117 0.6× 50 0.3× 315 2.0× 145 1.0× 26 622
Martin Diebold Germany 16 200 0.4× 240 1.2× 48 0.3× 242 1.6× 86 0.6× 39 708
Sara Pratesi Italy 17 105 0.2× 142 0.7× 136 0.8× 351 2.3× 40 0.3× 40 806
Catherine H. Orteu United Kingdom 17 147 0.3× 101 0.5× 193 1.2× 419 2.7× 25 0.2× 32 943
Miguel Guerrero Spain 13 269 0.6× 62 0.3× 100 0.6× 193 1.2× 54 0.4× 17 481

Countries citing papers authored by Neil Minton

Since Specialization
Citations

This map shows the geographic impact of Neil Minton's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Neil Minton with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Neil Minton more than expected).

Fields of papers citing papers by Neil Minton

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Neil Minton. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Neil Minton. The network helps show where Neil Minton may publish in the future.

Co-authorship network of co-authors of Neil Minton

This figure shows the co-authorship network connecting the top 25 collaborators of Neil Minton. A scholar is included among the top collaborators of Neil Minton based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Neil Minton. Neil Minton is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Martinez, Matthew W., et al.. (2024). THE CAMZYOS (MAVACAMTEN) RISK EVALUATION AND MITIGATION STRATEGY PROGRAM: RESULTS FROM 10 MONTHS POST-LAUNCH. Journal of the American College of Cardiology. 83(13). 354–354. 1 indexed citations
2.
Hernandez, Adrian F., Frederick A. Masoudi, Sula Mazimba, et al.. (2024). Design of DISCOVER-HCM: A Registry of Real-world Treatment Patterns and Outcomes of Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy. Journal of Cardiac Failure. 30. S4–S4. 2 indexed citations
3.
Cree, Bruce, Krzysztof Selmaj, Lawrence Steinman, et al.. (2022). Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Up to 5 years of follow-up in the DAYBREAK open-label extension trial. Multiple Sclerosis Journal. 28(12). 1944–1962. 30 indexed citations
4.
Selmaj, Krzysztof, Jeffrey A. Cohen, Gıancarlo Comı, et al.. (2021). Ozanimod in relapsing multiple sclerosis: Pooled safety results from the clinical development program. Multiple Sclerosis and Related Disorders. 51. 102844–102844. 26 indexed citations
5.
Minton, Neil, et al.. (2021). Pregnancy outcomes in the ozanimod multiple sclerosis clinical development program (2432). Neurology. 96(15_supplement). 3 indexed citations
6.
Colombel, Jean‐Frédéric, Michael Silver, James K. Sheffield, et al.. (2021). S745 Safety of Concurrent Administration of Ozanimod and Serotonergic Antidepressants in Patients With Ulcerative Colitis. The American Journal of Gastroenterology. 116(1). S343–S343. 1 indexed citations
7.
Feagan, Brian G., William J. Sandborn, Silvio Danese, et al.. (2020). Ozanimod induction therapy for patients with moderate to severe Crohn's disease: a single-arm, phase 2, prospective observer-blinded endpoint study. ˜The œLancet. Gastroenterology & hepatology. 5(9). 819–828. 107 indexed citations
8.
Persson, Rebecca, Marianne Ulcickas Yood, Neil Minton, et al.. (2020). Infections in patients diagnosed with multiple sclerosis: A multi-database study. Multiple Sclerosis and Related Disorders. 41. 101982–101982. 69 indexed citations
9.
Chiesa, Flaminia, Camilla Bengtsson, Sally Lee, et al.. (2020). Non-infectious comorbidity in patients with multiple sclerosis: A national cohort study in Sweden. Multiple Sclerosis Journal - Experimental Translational and Clinical. 6(3). 2455367729–2455367729. 13 indexed citations
10.
Dellon, Evan S., Margaret H. Collins, Marc E. Rothenberg, et al.. (2020). Long-term Efficacy and Tolerability of RPC4046 in an Open-Label Extension Trial of Patients With Eosinophilic Esophagitis. Clinical Gastroenterology and Hepatology. 19(3). 473–483.e17. 61 indexed citations
11.
Chiesa, Flaminia, Simona Conte, Camilla Bengtsson, et al.. (2020). Infections in patients with multiple sclerosis: A national cohort study in Sweden. Multiple Sclerosis and Related Disorders. 45. 102420–102420. 39 indexed citations
12.
Persson, Rebecca, Marianne Ulcickas Yood, Michael Wagner, et al.. (2020). Incident depression in patients diagnosed with multiple sclerosis: a multi‐database study. European Journal of Neurology. 27(8). 1556–1560. 8 indexed citations
13.
Hartung, Hans‐Peter, Bruce Cree, Krzysztof Selmaj, et al.. (2020). Low Rate of Infections With Long-term Use of Ozanimod in Relapsing Multiple Sclerosis Trials (1596). Neurology. 94(15_supplement). 2 indexed citations
14.
Cohen, Jeffrey A., Gıancarlo Comı, Krzysztof Selmaj, et al.. (2019). Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial. The Lancet Neurology. 18(11). 1021–1033. 197 indexed citations
15.
Comı, Gıancarlo, Ludwig Kappos, Krzysztof Selmaj, et al.. (2019). Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial. The Lancet Neurology. 18(11). 1009–1020. 205 indexed citations
16.
Persson, Rebecca, Sally Lee, Marianne Ulcickas Yood, et al.. (2019). Multi-database study of multiple sclerosis: identification, validation and description of MS patients in two countries. Journal of Neurology. 266(5). 1095–1106. 15 indexed citations
17.
Persson, Rebecca, Sally Lee, Marianne Ulcickas Yood, et al.. (2019). Incident cardiovascular disease in patients diagnosed with multiple sclerosis: A multi-database study. Multiple Sclerosis and Related Disorders. 37. 101423–101423. 31 indexed citations
18.
Persson, Rebecca, Marianne Ulcickas Yood, Michael Wagner, et al.. (2019). Increased Risk of Comorbidities in Patients Before and After Multiple Sclerosis Diagnosis and Initiation of Treatment: A Study Using the US Department of Defense Database (P4.2-058). Neurology. 92(15_supplement). 1 indexed citations
19.
Campagnolo, Denise I., et al.. (2018). Pregnancy Outcomes in the Ozanimod Nonclinical and Clinical Development Program (P4.363). Neurology. 90(15_supplement). 3 indexed citations
20.
Cavo, Michèle, Luciano Masini, Igor Wolfgang Blau, et al.. (2011). Post-Approval Safety Study (PASS) of Lenalidomide Compared with Other Treatments in Patients with Relapsed or Refractory Multiple Myeloma. Blood. 118(21). 1867–1867. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by P. Gjörstrup Breakdown of academic impact, for papers by D. Kingsbury Breakdown of academic impact, for papers by J. Woody Breakdown of academic impact, for papers by M. Mandel Breakdown of academic impact, for papers by S. Bubel Breakdown of academic impact, for papers by Alexandra Garcia Breakdown of academic impact, for papers by Martin Diebold Breakdown of academic impact, for papers by Sara Pratesi Breakdown of academic impact, for papers by Catherine H. Orteu Breakdown of academic impact, for papers by Miguel Guerrero
Rankless by CCL
2026